Advisory issued for Epzicom.
D000075202:Contraindications; D015224:Dideoxynucleosides; D004338:Drug Combinations; D004348:Drug Labeling; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir